We are live on
!
Find out more
MU
Mirova US Portfolio holdings
AUM
$8.81B
1-Year Est. Return
21.38%
This Fund
S&P 500
This Quarter
Est. Return
+11.86%
1 Year Est. Return
+21.38%
3 Year Est. Return
+80.7%
5 Year Est. Return
+106.85%
10 Year Est. Return
–
AUM
$2.29B
AUM Growth
+$546M
(+31%)
Cap. Flow
+$349M
Cap. Flow
% of AUM
15.21%
Top 10 Holdings %
Top 10 Hldgs %
72.22%
Holding
26
New
–
Increased
19
Reduced
6
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ecolab
ECL
|
+$71.2M |
| 2 |
Microsoft
MSFT
|
+$38.5M |
| 3 |
SBNY
Signature Bank
SBNY
|
+$38.2M |
| 4 |
Mastercard
MA
|
+$36.4M |
| 5 |
eBay
EBAY
|
+$34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$29.7M |
| 2 |
NVIDIA
NVDA
|
+$4.99M |
| 3 |
Danaher
DHR
|
+$3.2M |
| 4 |
Ormat Technologies
ORA
|
+$1.41M |
| 5 |
Xylem
XYL
|
+$1.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.9% |
| 2 | Financials | 19.51% |
| 3 | Healthcare | 16.46% |
| 4 | Consumer Discretionary | 10.92% |
| 5 | Materials | 8.3% |
Similar funds
MERSOM
CFB
MOACM
SWP
CB
WT
OAM
PEA
Mirova US's Q4 2020 Portfolio in Review
As of Q4 2020, Mirova US held 26 positions worth $2.29B, up 31% from $1.75B the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Mirova US deployed $349M of net new capital in Q4 2020, adding to 19 existing holdings.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 28% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was NVIDIA, an estimated $4.99M trimmed.
- Mirova US added most to Ecolab in Q4 2020, an estimated $71.2M increase.
- Mirova US's biggest Q4 2020 reduction was NVIDIA, cutting an estimated $4.99M.
- Mirova US fully exited Gilead Sciences in Q4 2020, selling an estimated $29.7M.
- Mirova US's ten largest holdings make up 72% of its $2.29B portfolio in Q4 2020.
- Mirova US opened 0 new positions and closed 1 in Q4 2020.
- Mirova US's portfolio value rose 31% quarter-over-quarter to $2.29B.
Based on Mirova US's 13F filing for Q4 2020, filed 16 Feb 2021.